Skip to main content
PLOS One logoLink to PLOS One
. 2020 Oct 15;15(10):e0240697. doi: 10.1371/journal.pone.0240697

The impact of brain iron accumulation on cognition: A systematic review

Holly Spence 1,*, Chris J McNeil 1, Gordon D Waiter 1
Editor: Efthimios M C Skoulakis2
PMCID: PMC7561208  PMID: 33057378

Abstract

Iron is involved in many processes in the brain including, myelin generation, mitochondrial function, synthesis of ATP and DNA and the cycling of neurotransmitters. Disruption of normal iron homeostasis can result in iron accumulation in the brain, which in turn can partake in interactions which amplify oxidative damage. The development of MRI techniques for quantifying brain iron has allowed for the characterisation of the impact that brain iron has on cognition and neurodegeneration. This review uses a systematic approach to collate and evaluate the current literature which explores the relationship between brain iron and cognition. The following databases were searched in keeping with a predetermined inclusion criterion: Embase Ovid, PubMed and PsychInfo (from inception to 31st March 2020). The included studies were assessed for study characteristics and quality and their results were extracted and summarised. This review identified 41 human studies of varying design, which statistically assessed the relationship between brain iron and cognition. The most consistently reported interactions were in the Caudate nuclei, where increasing iron correlated poorer memory and general cognitive performance in adulthood. There were also consistent reports of a correlation between increased Hippocampal and Thalamic iron and poorer memory performance, as well as, between iron in the Putamen and Globus Pallidus and general cognition. We conclude that there is consistent evidence that brain iron is detrimental to cognitive health, however, more longitudinal studies will be required to fully understand this relationship and to determine whether iron occurs as a primary cause or secondary effect of cognitive decline.

Introduction

Iron has many biological roles including the cycling of neurotransmitters, enzyme and mitochondrial function, ATP and DNA synthesis and myelin generation [14]. In the healthy human adult brain, the total concentration of iron is around 0–200μg per gram of tissue, typically being lower in the White Matter (WM) and cortical Grey Matter (GM) (<60 μg per gram) [2]. 90% of brain iron is stored in ferritin with only 0.05% of brain iron being present in the labile iron pool [5]. In healthy aging, iron accumulates heterogeneously in specific regions of the brain, bound mainly to ferritin and neuromelanin [6] and largely located in the deep GM nuclei [710]. There is a rapid increase in iron accumulation (different depending on brain region) from birth up until around 20 years old, at which point the accumulation rate slows in some regions, reaching a plateau in middle age and increasing again after 60 years old [1, 7]. Due to this relationship with age, brain iron has been the focus of many studies finding associations between regional brain iron levels and age-related cognitive decline, as well as several neurodegenerative diseases [4, 6].

Several theories as to the role of brain iron in cognitive decline have been suggested. Many of these mechanisms revolve around the ability of iron to induce oxidative stress via Fenton’s reaction [11]. During Fenton’s reaction, excess iron reacts with reactive oxygen species (ROS), such as hydrogen peroxide to produce highly reactive OH˙ radicals which can in turn induce iron release from mitochondrial iron-sulphur cluster proteins and iron storage proteins. Released iron can then undergo Fenton’s reaction, amplifying ROS generation [6, 12]. When ROS and free radicals generated via Fenton’s reaction exceed the antioxidant capacity of brain cells, oxidative stress is induced leading to loss of DNA integrity, lipid peroxidation, mitochondrial dysfunction, protein misfolding and ultimately neuronal cell death. This oxidative stress is thought to be exacerbated by the induction of neuroinflammation. Upregulation of HO-1 in glia is also thought to contribute to neurodegeneration as prolonged action may be involved in iron sequestration, intracellular stress and mitochondrial insufficiency [6, 1315]. Another potential mechanism by which brain iron levels could influence cognitive decline/neurodegeneration is Ferroptosis. This is an iron-dependent necrosis mechanism which is characterised by shrunken mitochondria with increased density and outer membrane rupture [16].

In terms of the mechanism by which iron accumulates, it has been shown in several studies that participants with Parkinson’s disease (PD) have an increased permeability of the blood brain barrier (BBB) and upregulation of iron transporters such as Lactotransferrin [5, 12, 17]. This would allow for the increased uptake of iron into the brain and may account for the increase of iron accumulation in the brain in neurodegenerative disease. Furthermore, in diseases such as Alzheimer’s disease (AD), PD and prion disease, iron is shown to associate with protein aggregates and in the case of Amyloid beta, it is thought that iron plays a role in the toxicity of these protein aggregates [1820]. Although these theories have been proposed, the full extent of the role of iron in cognitive decline and neurodegeneration remains unclear.

Although iron status measurement has been possible for many years, the emergence of novel techniques in magnetic resonance imaging have allowed for the specific, non-invasive measurement of brain iron. Techniques such as Susceptibility Weighted Imaging (SWI), R2* relaxation time and Quantitative Susceptibility Mapping (QSM) make use of the magnetic properties of iron in order to map the spatial distribution of iron in the brain from magnitude and phase images [21]. QSM is considered the most sensitive and specific technique for measuring iron in the brain non-invasively [22] and the ability of QSM to accurately measure brain iron has been validated in several post-mortem studies [23, 24]. It is hoped that such measures of brain iron will allow for further elucidation of the brain iron accumulation patterns and their relationship with cognitive decline and neurodegeneration.

This review will discuss the relationships between brain iron and cognition elucidated in human studies across a wide age range; in healthy adults as well as, in individuals with diseases including PD, AD, Type 2 Diabetes Mellitus with cognitive impairment, mild cognitive impairment (MCI) and Multiple Sclerosis (MS). We aim to present the current understanding of regional brain iron accumulation patterns and their relation to cognitive performance outcomes, in order to gain a greater understanding of the potential mechanisms underlying this iron-cognition relationship. We hypothesise that age-related regional increase in brain iron levels will correlate with impairment of specific regional cognitive function.

Methods

The PRISMA statement recommendations for systematic review were followed in this systematic review in order to provide high quality reporting [25, 26].

Information sources and eligibility criteria

A systematic electronic search strategy was generated at the start of this study. Electronic searching was carried out on 31st March 2020 using the following electronic databases: Embase Ovid (1974–31 March 2020), PubMed (Inception– 31 March 2020) and Psych Info (1806–31 March 2020). Studies were assessed for adherence to pre-determined inclusion/exclusion criteria detailed below.

Inclusion criteria

Studies were included in this review if they reported on the following:

  1. Human Studies measuring Brain iron level AND cognition

  2. Statistical comparison of brain iron and cognitive performance

  3. Published in English Language AND the full text was available

Exclusion criteria

Studies were excluded from this review if they were:

  1. Animal studies

  2. Measuring only systemic iron status (no measure of brain specific iron levels)

  3. Single case studies, Reviews, protocols editorials or conference abstract

  4. Studies investigating effects of maternal iron on offspring cognition

Search strategy

The full search strategies used for this review are detailed in Table 1.

Table 1. Search strategy.

Database Search terms
Embase Ovid (1974–31 March 2020) (("cognitive".ti OR "neurocognitive".ti OR "cognitive decline".ti OR "mental deterioration".ti OR "cognition".ti OR "brain function".ti OR "brain health".ti OR "cognitive ability".ti OR "cognitive health".ti OR "cognitive function".ti OR "neurological health".ti OR "neurological".ti) AND ("iron".ti OR "Fe".ti OR "ferric".ti OR "ferrous".ti OR "ferritin".ti OR "transferrin".ti OR "TfR".ti))
Pubmed (Inception—31 March 2020) (("cognitive"[title] OR "neurocognitive"[title] OR "cognitive decline"[title] OR "mental deterioration"[title] OR "cognition"[title] OR "brain function"[title] OR "brain health"[title] OR "cognitive ability"[title] OR "cognitive health"[title] OR "cognitive function"[title] OR "neurological health"[title] OR "neurological"[title] AND ("iron"[title] OR "Fe"[title] OR "ferric"[title] OR "ferrous"[title] OR "ferritin"[title] OR "transferrin"[title] OR "TfR"[title]))
Psycinfo (1806–31 March 2020) (("cognitive".ti OR "neurocognitive".ti OR "cognitive decline".ti OR "mental deterioration".ti OR "cognition".ti OR "brain function".ti OR "brain health".ti OR "cognitive ability".ti OR "cognitive health".ti OR "cognitive function".ti OR "neurological health".ti OR "neurological".ti) AND ("iron".ti OR "Fe".ti OR "ferric".ti OR "ferrous".ti OR "ferritin".ti OR "transferrin".ti OR "TfR".ti))

Study selection

All studies found in the electronic search were assessed for their eligibility for inclusion in this review by Holly Spence. Studies were included if they met all the inclusion criteria and included studies had their referenced papers reviewed for eligibility for inclusion. The included studies ultimately consisted of published articles and theses only.

Synthesis of results

The following study characteristics were extracted from each study for assessment of study quality and study comparison: Number of participants; participant gender ratio; participant average age; type of study design; measures of cognition used; measures of brain iron used; statistical methods used. Results which were statistically significant (p<0.05) were extracted and summarised from each study.

Quality assessment

Each study which satisfied the inclusion and exclusion criteria was assessed for quality via a 10-point based system using the following 10 criteria: (1) Does the study have a clearly defined research objective? (2) Does the study adequately describe the inclusion/exclusion criteria? (3) Is the sample size adequate? (4) Does the study report on the population parameters/demographics? (5) Does the study report detail on appropriate assessment of Cognition? (6) Does the study report detail of the assessment of iron? (7) Does the study provide an appropriate control group? (8) Does the study apply the appropriate statistical analyses? (9) Does the study adequately report the strength of results? (10) Do the authors report on the limitations of their study?

Results

Study selection

The electronic search of Embase Ovid, PubMed and PsychInfo yielded 643 citations in total. After duplicates were removed, 411 studies remained for screening. Once these studies were screened, 141 non-human studies were excluded, 4 papers were excluded due to being unavailable in English and 106 reviews, editorials and conference abstracts were removed. In total 6 studies were excluded due to being single case studies, 60 were excluded for not measuring brain iron and 6 were excluded for not measuring cognition. Finally, 24 studies did not assess statistically the relationship between iron and cognition and so were excluded, as well as 3 studies which measured only the effects of maternal iron on offspring cognition. A total of 28 studies remained for reference screening. After references were reviewed, a further 13 eligible studies were obtained. A total of 41 studies were therefore included in this review. The full details of the study selection process are outlined in Fig 1.

Fig 1. Flowchart detailing the study selection procedure.

Fig 1

Study characteristics

Study characteristics were collated and are presented in Tables 2 and 3; with Table 2 presenting details on overall study design and Table 3 presenting details on participants and study groups

Table 2. Study characteristics.

Study Reference Total Participants (n) Study Design Method of Cognitive Assessment Method of Iron Assessment Statistical Methods Used
Ayton et al., 2019 [27] 209 Cross-sectional study Word List Memory; Word List Recall and Word List Recognition from the procedures established by the CERAD; immediate and delayed recall of Story A from the Logical Memory subtest of the Wechsler Memory Scale- Revised; immediate and delayed recall of the East Boston Story; 15-item Boston Naming Test; Verbal Fluency; 15-item word reading test; Digit Span Forward; DSB; Digit Ordering; SDMT; Stroop colour naming; Stroop word reading; number comparisons; Judgement of Line Orientation; 16-item version of the Standard Progressive Matrices; Composite scores computed for each cognitive domain and for global cognition using standardized composite z-scores Post-mortem instrumental neutron activation analysis Multiple regression models; Bonferroni adjustment for multiple comparisons; Mixed-effects linear models of cognitive composite scores; Mediation analysis
Bartzokis et al., 2011 [28] 63 Cross-sectional study CVLT for verbal learning and memory; ACT for working memory; Digit Span subtest of WAIS III for attention span measure; TMT-A and B for processing speed, Digit Symbol subtest from WAIS-R to measure psychomotor speed MRI (1.5/0.5T) with FDRI Multiple regression analysis; Pearson’s correlations; Post hoc Fisher’s z-transformed values; Principle components analysis; Bonferroni correction for multiple comparisons
Blasco et al., 2014 [29] 43 Cross-sectional study WAIS-III; TMT; ROCF test; Stroop neuropsychological screening test; Iowa gambling task MRI (1.5T) with R2* Relaxometry Chi-squared for categorical variables; Students t test for quantitative variables; Mann-Whitney U test for non-normal distributed variables; Nonparametric spearman analysis; Multivariate linear regression modelling controlling for age, sex and BMI, Receiver operating characteristic analyses
Blasco et al., 2017 [30] 35 Longitudinal study ROCFT; TMT A and B; Verbal Fluency MRI (1.5T) R2* Relaxometry Voxel wise non-parametric permutation inference with 5000 randomised iterations to evaluate association of age and obesity variations in R2*; Continuous variables analysed with median and quartiles; Categorical variables analysed with frequencies; Non-parametric analyses considering non-normal distribution due to small sample size; Mann-Whitney U test for differences in study groups; Wilcoxon test for longitudinal intrasubject differences; Correlations assessed by Spearman rho analysis; Clustering analysis; Multivariate linear regression
Carpenter et al., 2016 [31] 39 Longitudinal Study DAS to measure overall general intelligence and cluster scores for verbal ability; non-verbal reasoning and spatial ability and reported as age-based standard scores MRI (3T) with QSM Mixed multiple regression models with age at scan as a covariate
Chen et al., 2018 [32] 27 Longitudinal Study NIH toolbox for cognition batteries; Executive function and attention; episodic memory; working memory and language processing summary scores MRI (3T) with SWI and QSM Unconditional logistic regression to compare ethnicity and education; Fishers test to assess ethnicity distribution between groups; Linear mixed modelling for longitudinal analyses; Compound symmetry covariance structure for within-subject correlations; Pearson correlation coefficients; Bonferroni method for multiple testing correction
Darki et al., 2016 [33] 46 Cross-sectional study Visuo-spatial working memory task MRI (3T) with QSM Students t test; ANOVAs; Bonferroni Correction for multiple comparisons
Daugherty, 2014 [34] 89 Longitudinal Study Listening span; n-back for digits; SPART; n-back for objects; Virtual Morris water maze MRI (4T) with SWI Latent growth curve model analyses; Latent change score model analyses; Missing data was estimated with full information maximum likelihood in Mplus; ANCOVA for adjusting volume to cranial size; Bootstrapping with bias correction for sample size, simple effects models; Bonferroni correction for multiple comparisons; Chi-squared statistic; Root mean square error of approximation (RMSEA); Comparative fit; Tucker-Lewis fit; Standardised root mean residual (SRMR)
Daugherty, Haacke and Raz, 2015 [35] 125 Longitudinal study Working memory (Listening span; Verbal N-back task; SPART; Non-verbal N-back task); Episodic memory (Logical memory subset of Wechsler Memory scale-revised) MRI (4T) with SWI and R2* relaxometry Longitudinal structural equation modelling; Univariate distributions; Tukey’s boxplots; Z-scores; Latent change score models; parallel process models; Bonferroni correction for multiple comparisons; Models bootstrapped with bias correction; Normal theory weighted chai squared test; root mean square error of approximation; Comparative fit index; Standardised root mean residual; Weighted root mean square residual, Reverse effects models
Daugherty et al., 2019 [36] 183 Cross-sectional study CES-D; MMSE; Verbal Fluency and Colour Word Interference Subtests of the D-KEFS MRI (3T) SWI z test; chi squared tests; comparative fit index (excellent fit when 0.90); root mean square of error approximation (good fit when <0.08); standardised root mean residual (good fit when <0.08)
Ding et al., 2009 [37] 50 Cross-sectional study MMSE MRI (1.5T) with phase imaging One-way ANOVA with LSD post hoc test; Students t-test; Mann-Whitney U test; Paired-sample t-test; Partial Spearman rank correlation coefficient
Du et al., 2018 [38] 60 Case-Control Study MMSE and MoCA MRI (3T) QSM Intraclass correlation coefficient for interobserver error (<0.4 Poor, 0.4–0.59 Fair, 0.6–0.74 Good, >0.74 Excellent); Pearson partial correlation for correlation analyses; Paired t test and Student t test
Fujiwara et al., 2017 [39] 67 Case-Control Study Verbal and visual memory tests; SRT; SPART; Info processing speed/working memory tests (SDMT and PASAT); Phonemic fluency test (WLG) MRI (4.7T) R2* Relaxometry and QSM Cognitive scores and imaged parameters compared using ANCOVAs; Hierarchic Linear regression models
Gao et al., 2017 [40] 90 Case-Control Study MMSE and MoCA MRI (3T) SWI Chi-squared tests for categorical variables; One-way ANOVA for comparison of groups using Fisher’s LSD posthoc test; Pearson correlation coefficient used to analyse relationship between quantitative variables; Serum ferritin had large variance so log10 serum ferritin was used in correlation analysis
Ge et al., 2007 [41] 31 Cross-sectional study WAIS-III; Digit Symbol-coding; ROCFT; D-KEFS; verbal fluency test; CVLT; WAIS-III; SDMT; D-KEFS Colour Word Interference Test; PASAT MRI (3T) with magnetic field correlation Least Squares Regression; Pearson Correlations Coefficients
Ghadery et al., 2015 [42] 336 Cross-sectional study Immediate memory recall and learning ability (Lern und Gedächtnis Test, word and digit association tasks and story recall, trail and design recall); Executive function (WCST, TMT-B and DSB, (part of the WAIS-III)); Psychomotor speed (Purdue Pegboard test). Each of 3 cog function measures was summarised by z scores and global cog function calculated as mean of 3 cognitive function measures MRI (3T) R2* Relaxometry Kolmogorov-Smirnov test; ANOVA with Kruskal-Wallis test for normally dist.; Difference in proportions chi-squared; Regression analyses; Family structure added to models as random effect; Mediation models with bootstrapping; All models adjusted for potential cofounders of age, sex, education, hypertension, diabetes, cardiac disease; Variation inflation factor for multicollinearity; Benjamin Hochberg false discovery rate method for multiple testing correction
Haller et al., 2010 [43] 102 Cross-sectional study MMSE; verbal fluency; digit span forward; shapes tests MRI (3T) SWI ANOVA with post hoc pairwise Tukey multiple comparison test for parametric demographic measures; Non parametric data analysed by Kruskal-Wallis group tests with post hoc pairwise Dunn multiple comparison test; Cerebral microhaemorrhages differences were analysed by Mann-Whitney tests; Differences in iron deposition were assessed by ANOVAs with post hoc Bonferroni multiple comparison test for comparing controls and MCI groups
Hect et al., 2018 [44] 57 Cross-sectional study IQ test calculated from Kaufman Brief Intelligence Test (2nd edition); W-J III NU (visual matching and cross out subtests); WAIS III (Digit symbol test) MRI (3T) R2* Relaxometry General linear models for age differences in iron in relation to cognition; hierarchical linear regression models to identify unique and shared variance bootstrapped with bias-correction and Bonferroni correction for multiple comparisons
House et al., 2006 [45] 23 Cross-sectional study CVLT to assess verbal learning and memory; MMSE; NART; DASS MRI (1.5T) with R2 Relaxometry Pearson product moment correlation coefficient; ANOVA; Two-tailed t tests; Chi-squared test; One-tailed t-test; ANCOVA with age as covariate; Partial Spearman rank correlation coefficient
Kalpouzos et al., 2017 [46] 37 Cross-sectional study Mental Imagery Memory task (Imagery then recall of scenes involving motion and involving no motion) MRI (3T) with R2* Relaxometry ANOVA; Partial correlations; ANCOVAs; Paired and 2-sample T-tests; Linear models; Cluster analyses; Bootstrapping analysis for small sample size
Larsen et al., 2020 [1] 818 Longitudinal Study Penn computerised neurocognitive battery (CNB) with 14 subtests assessing executive control; complex cognition; episodic memory; social cognition and motor speed MRI with R2* Relaxometry Interacquisition variability corrected using ComBat batch effect correction tool with age, sex, visit number and cognitive performance as covariates; Bonferroni correction for multiple comparisons; Generalised Additive Mixed Model for linear/non-linear age effects and cognitive effects; Bivariate smooth model and varying coefficient models; Bayesian information criterion for model selection; P values confirmed using parametric bootstrap likelihood ratio test
Li et al., 2015 [47] 132 Cross-sectional study Purdue-Pegboard-Test for manual dexterity and perceptual speed; Digit span test for verbal working memory; WCST to measure ability to display flexibility in face of changing rules; TMT-B for measuring executive functioning, psychomotor speed and visual scanning; Semantic Fluency Test; MMSE MRI (3T) with QSM Multiple Regression Modelling; Standardised z scoring susceptibility, demographic and behavioural variables; Factor analysis
Lu et al., 2015 [48] 76 Cross-sectional study MMSE MRI (3T) with SWI ANCOVA; correction for multiple comparisons by Levene's Test for Equality of Variances, Spearman Correlations for MMSE-Angle Radian value relationship
Modica et al., 2015 [49] 112 Cross-sectional study SDMT for visual information processing speed; 3 second interval PASAT for auditory information processing; correct sorts component of D-KEFS; total learning portion of the second edition CVLT and the total learning portion of the BVMT-R MRI (3T) SWI MS and controls cognition compared by One-way ANOVA; Z scores calculated for each cog test based on controls; Partial correlations controlling for age and education; Pearson correlations assessed between structure mean phase and volume of structure; Hierarchical linear regression analysed mean phase-cognitive test relationship
Murakami et al., 2018 [50] 49 Cross-sectional study MMSE; FAB for frontal lobe function; MRS for neurological disturbance Brain-type Transferrin assessed via SDS-PAGE and PVL lectin staining Parametric/non-parametric was assessed by Kolmogorov-Smirnov or Shapiro-Wilk method; Parametric variables assessed with Mean and SD; Students t test; Welch test; Multiple comparisons Dunnett’s test; Pearson correlation coefficients
Penke et al., 2012 [51] 143 Longitudinal study At 11 years old—MHT number 12 for general IQ; At 70 years old—MHT; At 72 years old—WAIS-III including symbol search, digit symbol, matrix reasoning, letter-number sequencing, DSB and block design; NART and WTAR MRI (1.5T) with MCMxxxVI method (multispectral colouring modulation and variance identification) for iron quantification Age was controlled for in all analyses; Total iron volume was standardised to brain volume for each subject to derive % of iron deposit in brain tissue; Tobit regressions with iron deposition as dependant variable to calculate censored correlations with cognition
Pinter et al., 2015 [52] 69 Cross-sectional study EDSS; Brief Battery of Neuropsychological Tests; SRT; 10/36-SPART; SDMT; PASAT; WLG; Composite z score to measure overall cognitive function MRI (3T) with R2* relaxometry Pearson Correlation; Point-biserial Correlation; Durbin-Watson-test; Variance Inflation Factor; Hierarchical regression models; Multivariate model including strongest predictors for overall cognitive function and subdomains to assess additive value of multiple MRI-parameters in predicting cognition
Qin et al., 2011 [53] 30 Cross-sectional study MMSE MRI (3T) with R2* Relaxometry Pearson correlation assay for Linear regression; two tailed t-test; Students-Newman-Keuls test for ANOVA; Linear correlation test
Rodrigue et al., 2013 [54] 113 Cross-sectional study Immediate and delayed recall measures from memory for names (W-J III NU) and logical memory tests (Wechsler Memory Scale Revised) MRI (1.5T) with T2* relaxometry Structural equation modelling with latent variables; All memory and anatomical measures log transformed to alleviate skew; Bootstrapping to combat modest sample size with bias correction (500 iterations of whole sample); Chi-squared statistic; Root mean square error of approximation (RMSEA); Comparative fit; Tucker-Lewis fit indices; Standard root mean residual (SRMR); Akaike and sample-size adjusted Bayesian information criteria; James and Brett method for evaluation of indirect effects
Rodrigue et al., 2020 [55] 166 Cross-sectional study Executive function (Subsets of the D-KEFS—Verbal fluency, TMT and Colour word interference test); and Subsets of the WCST and Working Memory (WAIS-IV subtests, Digit span forward backward, Listening Span Task); Both functions are standardised together to form z scores MRI (3T) with R2* Relaxometry General linear models, Age, iron, age x iron interaction, whole brain CBF, sex and task response time were used as between subjects 2nd level covariates for linear modelling; All covariate mean centred to avoid bias in regression coefficients from multicollinearity; Cluster corrections calculated using non-parametric mapping toolbox
Salami et al., 2018 [56] 42 Cross-sectional study Purdue Pegboard Task MRI (3T) with R2* Relaxometry and QSM Two sample t-test; Multivariate model selection with sex as covariate; Partial correlations between iron content and connectivity; MANCOVA; Comparison between correlations conducted using Steigers z-test
Schmalbrock et al., 2016 [57] 29 Cross-sectional study MMSE; WTAR and the brief repeatable battery to assess general cognition; computerised versions of Flanker and Stroop tasks to assess inhibitory control MRI (7T) with QSM and R2* relaxometry z score deviation of >2.5SDs from mean were classed as outliers; normality tested via Shapiro-Wilk test; corrected skewed data with square root transformation; Pearson correlations; subtracted linear regression fit of QSM with age and EDSS with disease duration from measured data to control for these influences; semi partial correlations
Smith et al., 2010 [58] 20 Cross-sectional study CDR Histochemistry (7% Potassium ferrocyanide in 3% HCL visualised by treating with 0.75mg/ml 3-3-diaminobenzidine in tris buffer with H2O) Students t test
Steiger et al., 2016 [59] 62 Cross-sectional study Verbal Learning and Memory test MRI (3T) with R2* relaxometry Two sample t-test; Familywise error correction for multiple comparisons; Whole-brain linear regression modelling (Scores were used as individual regressors on the probability maps)
Sullivan et al., 2009 [60] 10 Retrospective Study MMSE; Mattis Dementia Scale (5 subtests–memory, arithmetic, construction, conceptualisation and initiation/preservation); Digit symbol test; Fine Finger Movement Test to assess upper limb speed; Two choice Task to assess reaction time and movement time MRI (1.5T and 3T) with Field Dependent R2 increase Pearson product-moment correlations for relationships between iron and cognitive tests; due to small sample size, parametric correlations were confirmed with non-parametric spearman rank order tests
Sun et al., 2017 [61] 39 Cross-sectional study Attention-executive function (Chinese modified version of TMT; modified version of Stroop Colour-Word Test and Verbal Fluency Test), Memory Function (Chinese modified version of AVLT for short and long delay free recall and ROCF delayed recall test); Language function (Boson Naming Test) and Visuospatial Function (ROCF copy test); Z score calculated for each function and a composite z score for all functions MRI (3T) with QSM Independent 2 sample t-test; Chi squared for calculating gender heterogeneity between groups; Non-normally distributed data was compared using Mann-Whitney U test; Inter-rater reliability among all regions = 0.947 for ROI segmentation; Correlation analyses with age and gender as covariates for z score-iron correlations
Thomas et al., 2020 [62] 137 Cross-sectional study MoCA; MDS- UPDRS- III; REM-sleep behaviour disorder score; Sense of smell; Depression; visual acuity as assessed by LogMAR; Colour vision D15 test; Contrast sensitivity using Pelli-Robson chart; Cats and Dogs task 25 and Biological Motion test MRI (3T) with QSM Age and total intracranial volume controlled for in imaging analyses as nuisance covariates; Permutation based regression analyses; Wilcoxon rank-sum tests; QSM values age-corrected using covariance method
Valdes-Hernandez et al., 2015 [63] 676 Cross-sectional study Fluid intelligence (g-fluid) consisting of; Digit symbol substitution test, DSB, symbol search, letter-number sequencing, block design and matrix reasoning. General processing speed (g-speed) consisting of; simple reaction time and choice reaction time, inspection time test, digit symbol substitution and symbol search. General memory (g-memory) consisting of logical memory total, verbal paired associates (both at total, immediate and delayed recall) and spatial span total score, letter-number sequencing and DSB. MRI (1.5T) T1/T2*W Total and regional iron and WMH volumes were standardised and presented as % of intracranial volume, age was added as covariate of all models; volumes of iron and WMH were positively skewed and so were log transformed prior to analysis; Multivariate and Bivariate regression models were performed
Van Bergen et al., 2016 [64] 37 Cross-sectional study MMSE, MoCA, verbal learning and memory test; Wechsler Memory Scale; Boston naming test; TMT-A and B MRI (7T) QSM One-Way MANCOVA for differences between groups; Cohens d for effect size; Spearman’s rho
Wang et al., 2013 [65] 60 Cross-sectional study MMSE; CDR MRI (3T) with SWI Pearson correlation coefficients; ANOVA; Fish-Least significant difference (LSD) test
Yang et al., 2018 [66] 90 Case-Control Study AVLT; complex figure test; digit symbol coding test; digit span test; verbal fluency test; TMT-A and B MRI (3T) SWI Distribution assessed using Kolmogorov-Smirnov test; ANOVAs for normally distributed continuous data and LSD test used for post hoc analysis; Kruskal-Wallis H test used for non-normally distributed or unequal variances data and Mann-Whitney U test was used for posthoc analysis with sig level adjusted by Bonferroni correction; Chi squared test to compare proportions; Independent 2 sample t test used to assess diabetes duration

CVLT = California Verbal Learning Test; ACT = Auditory Consonant Trigrams; TMT-A and -B = Trail Making Task -A and -B; WAIS-III = Wechsler Adult Intelligence Scaled Third Edition; ROCF = Rey-Osterrieth Complex Figure; DAS = Differential Abilities Scale; CES-D = Centre for Epidemiologic Studies Depression Scale; MMSE = Mini Mental State Examination; D-KEFS = Delis-Kaplan Executive Function Test Battery; MoCA = Montreal cognitive assessment; SRT = Selective Reminding Task; SPART = Spatial Recall Test; SDMT = Symbol Digit Modalities Test; PASAT = Paced Auditory Serial Addition Test; DSB = Digit Span Backwards; W-J III NU = Woodcock-Johnson III Normative Update for processing speed; NART = National Adult Reading Test; DASS = Self-evaluated stress, anxiety and depression questionnaire; WCST = Wisconsin Card Sorting Test; BVMT-R = Brief Visuospatial Memory Test–Revised; MRS = Modified Rankin Scale; MHT = Moray House Test; WTAR = Wechsler Test of Adult Reading; EDSS = Expanded Disability Status Score; WLG = Word List Generation; CDR = Clinical Dementia Rating Scale; AVLT = Auditory Verbal Learning Test; MDS-UPDRS = 2 Year Risk of cognitive decline score made up of Movement Disorder Society Unified Parkinson’s Disease Rating Scale motor part 3.

Table 3. Participant characteristics.

Study Reference Total Participants (n) Participants (Control group) Participants (Study group 1) Participants (Study group 2) Participants (Study group 3)
n Gender Ratio (Men: Women) Mean Age at baseline (years) Group n Gender Ratio (Men: Women) Mean Age at baseline (years) Group n Gender Ratio (Men: Women) Mean Age at baseline (years) Group n Gender Ratio (Men: Women) Mean Age at baseline (Mean years ± SD) Group
Ayton et al., 2019 [27] 209 69 46:23 87.8 ± 6.0 Cognitively normal subjects with low AD pathology post-mortem 14 07:07 92.9 ± 4.5 AD patients with low pathology post-mortem 71 51:20 89.9 ± 6.5 Cognitively normal subjects with high AD pathology post-mortem 55 36:19 90.7 ± 5.1 AD patients with high AD pathology post-mortem
Bartzokis et al., 2011 [28] 63 - - - - 63 33:30 67.0 ± 6.1 Healthy, Cognitively normal Adults - - - - - - - -
Blasco et al., 2014 [29] 43 20 10:10 48.8 ± 9.5 Healthy Adult age and sex matched non-obese controls 23 10:13 50.4 ± 7.7 Middle aged Obese Subjects with type 2 Diabetes - - - - - - - -
Blasco et al., 2017 [30] 35 18 10:08 (39–56.25) No mean given Age and sex matched healthy non-obese adult controls 17 06:11 (48–58) No mean given Obese adults - - - - - - - -
Carpenter et al., 2016 [31] 39 - - - - 39 17:22 9.51 ± 1.25 Healthy Children - - - - - - - -
Chen et al., 2018 [32] 27 13 00:13 68.2 ± 6.1 Age matched women without breast cancer 14 00:14 66.3 ± 5.3 Women aged 60+ with breast cancer having adjuvant chemotherapy - - - - - - - -
Darki et al., 2016 [33] 46 - - - - 25 16:09 29.1 ± 4.5 Healthy Adults 21 12:08 6.73 ± 0.27 Healthy Children - - - -
Daugherty, 2014 [34] 89 - - - - 89 26:63 55.18 ± 12.85 Healthy Adults - - - - - - - -
Daugherty, Haacke and Raz, 2015 [35] 125 - - - - 125 37:88 52.53 ± 14.91 Healthy adults assessed at baseline 78 24:54 56.87 ± 12.82 Heathy adults followed up after 2 years - - - -
Daugherty et al., 2019 [36] 183 - - - - 183 76:107 53.68 ± 18.96 Health Adults - - - - - - - -
Ding et al., 2009 [37] 50 24 09:15 69.40 ± 11.38 Healthy Age-matched controls 26 08:18 70.96 ± 8.55 AD patients - - - - - - - -
Du et al., 2018 [38] 60 30 10:20 66.2 ± 7.8 Healthy Adult Controls 30 09:21 68.3 ± 6.6 Adults with mild to moderate Alzheimer's Disease - - - - - - - -
Fujiwara et al., 2017 [39] 67 27 09:18 47.51 ± 10.09 Healthy Adult Controls 40 13:27 49.08 ± 10.03 Adult Multiple Sclerosis Patients - - - - - - - -
Gao et al., 2017 [40] 90 30 17:13 72.86 ± 5.75 Age, Sex and Education matched healthy adult controls 30 13:17 75.2 ± 5.75 Adults with Mild Cognitive Impairment 30 18:12 74.83 ± 4.52 Adults with Alzheimer's Disease - - - -
Ge et al., 2007 [41] 31 14 05:09 39 Healthy adult controls 17 03:14 44 Relapsing-Remitting Multiple Sclerosis Patients - - - - - - - -
Ghadery et al., 2015 [42] 336 336 132:204 median age 67 (55–72) Healthy Adult Participants - - - - - - - - - - - -
Haller et al., 2010 [43] 102 35 09:26 63.7 ± 5.1 Healthy adult controls 40 13:27 65.4 ± 5.4 Adults with stable mild cognitive impairment 27 15:12 64.4 ± 4.6 Adults with progressive mild cognitive impairment - - - -
Hect et al., 2018 [44] 57 - - - - 57 19:38 12.5 ± 2.36 Healthy Children and Adolescents - - - - - - - -
House et al., 2006 [45] 23 11 03:08 70.7 ± 6.9 Healthy Adult Controls 6 02:04 69.2 ± 6.8 Elderly participants with memory complaints but no objective cognitive impairment 6 01:05 75.5 ± 8.8 Elderly participants with memory complaints and objective cognitive impairment - - - -
Kalpouzos et al., 2017 [46] 37 - - - - 22 10:12 36.8 ± 4.3 Healthy Younger Adults 15 08:07 69.7 ± 2.7 Healthy Older Adults - - - -
Larsen et al., 2020 [1] 818 - - - - 818 389:429 14.84 ± 3.57 Healthy Adolescents - - - - - - - -
Li et al., 2015 [47] 132 - - - - 132 54:78 64.5 ± 10.64 Healthy, Cognitively normal Adults - - - - - - - -
Lu et al., 2015 [48] 76 37 19:18 38.51 ± 13.21 Healthy Adult Controls 39 22:17 38.54 ± 13.15 Patients with chronic mild traumatic brain injury - - - - - - - -
Modica et al., 2015 [49] 112 27 10:17 41.9 ± 10.7 Healthy demographically matched controls 85 26:59 46.0 ± 9.2 Multiple Sclerosis (MS) Patients - - - - - - - -
Murakami et al., 2018 [50] 49 15 10:05 74.9±6.2 Healthy Adult Controls (without iNPH) 34 24:10 74.6±5.6 Patients with iNPH (idiopathic normal pressure hydrocephalus) - - - - - - - -
Penke et al., 2012 [51] 143 143 69:74 71.9 ± 0.3 Healthy Nondemented Adults - - - - - - - - - - - -
Pinter et al., 2015 [52] 69 - - - - 17 05:12 33.1 ± 9.1 Clinically Isolated Syndrome MS patients 47 18:29 35.8 ± 10.5 Relapsing-Remitting MS patients 5 03:02 41.8 ± 9.3 Secondary Progressive MS patients
Qin et al., 2011 [53] 30 15 07:08 70 Healthy age and sex matched controls 15 07:08 69.8 Alzheimer's disease patients - - - - - - - -
Rodrigue et al., 2013 [54] 113 - - - - 113 57:76 53.96 ± 15.39 Healthy Adults - - - - - - - -
Rodrigue et al., 2020 [55] 166 - - - - 166 98:68 52.75 ± 19.06 Healthy non-cognitively impaired adults - - - - - - - -
Salami et al., 2018 [56] 42 - - - - 25 12:13 36.2 ± 4.4 Healthy Younger Adults 17 09:08 70.1 ± 3.1 Healthy Older Adults - - - -
Schmalbrock et al., 2016 [57] 29 - - - - 29 01:28 43.4 ± 9.7 Relapsing-Remitting Multiple Sclerosis Patients - - - - - - - -
Smith et al., 2010 [58] 20 5 - (Ranging 80–95) Cognitively and pathologically normal age-matched controls 4 - (Ranging 83–93) Adults with Pre-clinical AD 11 - (Ranging 74–102) Adults with mild cognitive impairment - - - -
Steiger et al., 2016 [59] 62 - - - - 31 14:17 67.3 ± 6.2 Healthy Elderly Participants 31 17:14 24.8 ± 2.8 Healthy Young Participants - - - -
Sullivan et al., 2009 [60] 10 - - - - 10 05:05 72.2 Healthy, non-demented, Elderly Adults - - - - - - - -
Sun et al., 2017 [61] 39 19 15:04 65.11 ± 3.71 Age, gender and education matched controls with Subcortical Ischaemic Vascular Disease (SIVD) but without cognitive impairment 20 16:04 63.40 ± 7.98 SIVD patients with subcortical vascular mild cognitive impairment (svMCI) - - - - - - - -
Thomas et al., 2020 [62] 137 37 16:21 66.1 ± 9.4 Healthy age matched controls 100 52:48 66.4 ± 7.7 Parkinson's Disease patients within 10 years of diagnosis - - - - - - - -
Valdes-Hernandez et al., 2015 [63] 676 - - - - 676 372:328 in original sample of 700 72.7±0.7 in original sample of 700 Healthy Elderly Participants - - - - - - - -
Van Bergen et al., 2016 [64] 37 22 14:08 71.91 ± 5.25 Healthy Adult Controls 15 10:05 75.27 ± 7.63 Adults with MCI - - - - - - - -
Wang et al., 2013 [65] 60 18 1.43 70.52 ± 6.91 Healthy Age matched controls 22 0.92 74.45 ± 8.24 amnestic mild cognitive impairment patients 20 1.32 73.37 ± 9.81 Alzheimer's Disease patients - - - -
Yang et al., 2018 [66] 90 30 14:16 53.17 ± 6.57 Age, Sex and Education matched healthy adult controls 30 19:11 54.97 ± 5.54 Adults with Type 2 Diabetes Mellitus without Mild Cognitive Impairment 30 12:18 55.9 ± 6.54 Adults with Type 2 Diabetes Mellitus with Mild Cognitive Impairment - - - -

Quality assessment

All included studies were assessed for quality using a 10-point-based scoring system and each score was converted to a % Quality Score (QS). The quality scores for all studies can be seen in Table 4. 26 of the 41 assessed studies were of high quality (QS>90%), 14 were of very good quality (QS of 80%-90%) and 1 study was of good quality (QS of 70%-80%).

Table 4. Quality scores.

Reference 1 2 3 4 5 6 7 8 9 10 Quality Score
Ayton et al., 2019 [27] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 0.50 90.00%
Bartzokis et al., 2011 [28] 1.00 1.00 0.50 1.00 1.00 1.00 0.50 1.00 1.00 1.00 90.00%
Blasco et al., 2014 [29] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Blasco et al., 2017 [30] 1.00 1.00 0.50 0.50 1.00 1.00 1.00 1.00 1.00 0.00 80.00%
Carpenter et al., 2016 [31] 1.00 1.00 0.50 1.00 1.00 1.00 0.50 1.00 1.00 1.00 90.00%
Chen et al., 2018 [32] 1.00 1.00 0.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 85.00%
Darki et al., 2016 [33] 1.00 1.00 0.50 1.00 0.50 1.00 0.50 1.00 1.00 0.50 80.00%
Daugherty, 2014 [34] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Daugherty, Haacke and Raz, 2015 [35] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Daugherty et al., 2019 [36] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Ding et al., 2009 [37] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Du et al., 2018 [38] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Fujiwara et al., 2017 [39] 1.00 1.00 0.50 1.00 1.00 1.00 0.50 1.00 1.00 1.00 90.00%
Gao et al., 2017 [40] 1.00 1.00 0.50 1.00 0.50 1.00 1.00 1.00 1.00 0.50 85.00%
Ge et al., 2007 [41] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.00 85.00%
Ghadery et al., 2015 [42] 1.00 1.00 1.00 1.00 0.50 1.00 0.50 1.00 1.00 1.00 90.00%
Haller et al., 2010 [43] 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 95.00%
Hect et al., 2018 [44] 1.00 1.00 0.50 0.50 1.00 1.00 0.50 1.00 1.00 1.00 85.00%
House et al., 2006 [45] 1.00 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 80.00%
Kalpouzos et al., 2017 [46] 1.00 1.00 0.50 1.00 1.00 1.00 0.50 1.00 1.00 0.50 85.00%
Larsen et al., 2020 [1] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Li et al., 2015 [47] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Lu et al., 2015 [48] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Modica et al., 2015 [49] 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 100.00%
Murakami et al., 2018 [50] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.50 90.00%
Penke et al., 2012 [51] 1.00 1.00 1.00 1.00 1.00 0.75 1.00 1.00 1.00 1.00 97.50%
Pinter et al., 2015 [52] 1.00 1.00 0.50 1.00 1.00 1.00 0.00 1.00 1.00 1.00 85.00%
Qin et al., 2011 [53] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.00 85.00%
Rodrigue et al., 2013 [54] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Rodrigue et al., 2020 [55] 1.00 1.00 1.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 95.00%
Salami et al., 2018 [56] 1.00 1.00 0.50 1.00 0.50 1.00 0.50 0.50 1.00 1.00 80.00%
Schmalbrock et al., 2016 [57] 1.00 1.00 0.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 80.00%
Smith et al., 2010 [58] 1.00 1.00 0.00 0.50 0.50 1.00 1.00 1.00 1.00 0.00 70.00%
Steiger et al., 2016 [59] 1.00 1.00 0.50 1.00 1.00 1.00 0.50 1.00 1.00 1.00 90.00%
Sullivan et al., 2009 [60] 1.00 1.00 0.00 1.00 1.00 1.00 0.50 1.00 1.00 1.00 85.00%
Sun et al., 2017 [61] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 95.00%
Thomas et al., 2020 [62] 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 100.00%
Valdes-Hernandez et al., 2015 [63] 1.00 1.00 1.00 0.50 1.00 1.00 0.50 1.00 1.00 1.00 90.00%
Van Bergen et al., 2016 [64] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.50 90.00%
Wang et al., 2013 [65] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.50 90.00%
Yang et al., 2018 [66] 1.00 1.00 0.50 1.00 1.00 1.00 1.00 1.00 1.00 0.00 85.00%

Criteria: (1) Does the study have a clearly defined research objective? (2) Does the study adequately describe the inclusion/exclusion criteria? (3) Is the sample size adequate? (4) Does the study report on the population parameters/demographics? (5) Does the study report detail on appropriate assessment of Cognition? (6) Does the study report detail of the assessment of iron? (7) Does the study provide an appropriate control group? (8) Does the study apply the appropriate statistical analyses? (9) Does the study adequately report the strength of results? (10) Do the authors report on the limitations of their study?

Summary of results

The key findings relating to the brain iron-cognition relationship were extracted from each study in this review and are summarised in Table 5. 11 of the reviewed papers showed a significant relationship between whole brain iron concentration and measures of cognition (including memory, general intelligence, visual performance, processing speed, social cognition and BOLD modulation). Every other study reviewed reported significant associations between iron levels in specific brain regions and individual measures of cognition, as presented in Fig 2.

Table 5. Summary of results.

Reference Summary of Findings relating iron to cognition
Ayton et al., 2019 [27] Inferior temporal iron levels were increased only in people with clinical diagnosis of dementia who also had moderate (P = 0.0003) and high pathology (P = 0.0190) and fit the CERAD criteria for probable (P = 0.0066) and definite pathology (P = 0.0003), and Braak criteria IV (P = 0.0067) and V (P = 0.0031); In people with high AD pathology, iron was strongly associated (P<0.0001) with the rate of decline in Global Cognition composite; mediation analysis showed that iron levels mediated 17% of the effect of NFTs on Global Cognition; In subjects with low AD pathology, elevated inferior temporal iron burden was associated with decline in global cognitive score (P = 0.001), but not the individual cognitive domain scores
Bartzokis et al., 2011 [28] Significant negative association between HP iron and episodic memory in men only (p = 0.003); Significant effect of iron genes on association between BG iron and working memory/attention score (p = 0.006); Significant correlation between BG iron and working memory/attention in those without H63D and TfC2 genes (r = -0.49, p = 0.005)
Blasco et al., 2014 [29] LN R2* values were associated with worse scores in the digit span test (P = 0.011), the ROCF test (P = 0.001), the TMT part A (P = 0.01), and the Iowa Gambling Task test (P = 0.025); Worse performance in the TMT-A were also associated with R2* in CN (P = 0.001) and HS (P = 0.007); HP R2* was associated with worse performance in the ROCF copy test (P = 0.016); HS and HP R2* cut off values discriminate score differences on the deferred memory test (P = 0.039) and the copy ROCF test (P = 0.023), respectively
Blasco et al., 2017 [30] Increase in R2* negatively correlated with change in visual spatial construction ability and immediate memory (p<0.05); Copy memory scores were inversely associated with R2* at the L-CN (r = 20.409; P = 0.034), L- and R- PA (r = 20.383; P = 0.048 and r = 20.524; P = 0.005, respectively), and R-PU (r = 20.575; P = 0.002); Immediate and deferred memory scores were inversely associated with R2* at the R-TH (r = 20.403; P = 0.037 and r = 20.395; P = 0.041); Worse TMT-A scores were associated with increased R2* at R- and L-PA (r = 0.440; P = 0.024 and r = 0.529; P = 0.005)
Carpenter et al., 2016 [31] Significant positive association between mean iron in basal ganglia and spatial IQ (p = 0.02); Iron in the R-CN (p<0.01), L-CN (p<0.05) and SN (p<0.05) had significant positive association with spatial IQ, but only R-CN relationship was withheld after correction for multiple comparisons; No association between spatial IQ and iron in GP, PU or TH
Chen et al., 2018 [32] Significant correlation between brain iron in GP and fluid composite score in control group (p<0.01); Baseline PU brain iron is negatively associated with changes in oral reading recognition test scores in the control group (p<0.01)
Darki et al., 2016 [33] Significant correlation between CN iron working memory performance in children (r = 0.64, p = 0.004) and adults (r = 0.46, p = 0.04); mainly driven by the R-CN in children; Other subcortical nuclei were not significantly correlated to working memory performance after Bonferroni correction for multiple comparisons
Daugherty, 2014 [34] Greater iron content at baseline was associated with slower iron accumulation in CN (p<0.05) and PU (p = 0.05); Higher metabolic syndrome score was associated with higher iron in the CN (p = 0.003) and LQ (p = 0.02); Inflammation score was unrelated to iron content; Non-verbal working memory didn’t change with age (p = 0.76); Verbal working memory improved over two years (p<0.001); Virtual Morris water maze test score was unrelated to iron or volume in any region
Daugherty, Haacke and Raz, 2015 [35] Cognitive switching ability was found to be inversely proportional to striatal iron (p<0.001)
Daugherty et al., 2019 [36] Greater baseline CN iron was associated with lesser improvement in working memory over 2 years (p = 0.01); Change in verbal working memory was unrelated to iron in the PU (p>0.52) or HP (p>0.17); Episodic memory wasn’t associated with baseline iron (p>0.31)
Ding et al., 2009 [37] Mean MMSE score was significantly lower in AD patients than controls (p<0.001); AD group showed significantly lower phase value in all brain structures measured (p<0.05); Phase value in R-head of HP had positive correlation with MMSE score (r = 0.603, p = 0.000) and negative correlation with disease duration (r = -0.677, p = 0.013)
Du et al., 2018 [38] Bilateral CN and PU susceptibility values are significantly higher in AD patients than controls (p<0.05); Bilateral RN susceptibility was significantly lower in AD patients than controls (p<0.05); left CN susceptibility is correlated with a decrease in MMSE score (p<0.01) and MoCA score (p<0.05)
Fujiwara et al., 2017 [39] Cognitive z scores were negatively associated with GP QSM (p = 0.03); No other QSM scores were correlated with cognition; Cognitive z score was (non significantly) related to GP R2* (p = 0.099); Controls showed no significant relationships between iron measures and cognition
Gao et al., 2017 [40] MMSE and MoCA was significantly higher in AD than both MCI and controls and was significantly higher in MCI than controls (p<0.05); L-DN, L-CN, PU of MCI group had significantly lower phase than controls; DN, R-RN, PU of AD group had significantly lower phase than MCI group; HP, DN, RN, CN, GP, PU and L-TC phase in AD group were significantly lower than controls; Lower Phase was significantly correlated with higher brain iron concentration (p<0.05)
Ge et al., 2007 [41] Iron was significantly higher in MS patients than controls in GP (p = 0.007), PU (p = 0.002), TH (p = 0.03); Significant correlation between Magnetic Field Correlation for iron (MFC) value in the TH and the CVLT test performance (r = -0.42, p = 0.04) and RCFT performance (r = -0.50, p = 0.03); MFC in the PU correlated DSB test performance (r = 0.45, p = 0.03)
Ghadery et al., 2015 [42] Higher age associated with lower education level, higher frequency of risk factors, worse cognitive performance, greater extent of focal brain lesions and lower brain volume (p<0.05); Higher iron load in PA related inversely with all cognitive measures except memory; R2* in PU was related to global cognitive function and psychomotor speed (p<0.05); No relationship between R2* in neocortex or HP and cognition; Associations between R2* iron and cognition were strongest in ages above 71; R2* iron in the pallidum accounted for 9% of the age-related variance in executive function, 7% in global cognitive function, and 8% in psychomotor speed; R2* iron in the PU accounted for 24% of the age-related variance in executive function, 18% in global cognitive function, and 21% in psychomotor speed
Haller et al., 2010 [43] There was a significantly increased iron concentration in R-PA and R-SN in MCI groups compared to controls (p<0.01); There was significantly decreased iron concentration in the R-RN in MCI groups compared to controls (p<0.05); No difference in iron concentration was found in any regions between stable and progressive MCI
Hect et al., 2018 [44] Brain iron in CN (p = 0.03), PU (p<0.01), GP (p = 0.04) and SN (p<0.01) correlated with general intelligence scores; Brain iron in the CN (p<0.001) and PU (p<0.01) correlated processing speed; HP (p>0.69) and RN (p>0.33) iron content were unrelated to cognition; Greater general brain iron content predicted faster processing speed (p = 0.02) and better general intelligence (p = 0.01)
House et al., 2006 [45] Least cognitively impaired memory-complaint group (MC1) had significantly higher R2 in R-temporal cortex and significantly lower R2 in the L-internal capsule compared to controls; MC1 and MC2 groups showed significant correlation between R2 and immediate, short-delay and long-delay free recall scores in CVLT in TH and RN (r = -0.62 to -0.77, p<0.04); R2 in the RN was negatively correlated to MMSE scores (p<0.02); Negative correlation coefficients were more frequently associated with R2 in GM regions for the immediate free recall scores (p = 0.001), SDFR cognitive score (p = 0.0002) and LDFR test scores (p = 0.0002)
Kalpouzos et al., 2017 [46] Higher striatal iron in the older group was associated with poorer recall in motor condition (p = 0.02); Striatal iron was not significantly associated with recall in the younger adults (p>0.7); Bootstrapping analysis indicated reliable association between striatal R2* and memory performance in older group; Greater striatal iron was associated with less inferior frontal cortex activation when age and striatal volume were controlled for (p = 0.05); Higher iron in R-PU was associated with lower activity in the R-PU when controlling for age and R-PU volume (p = 0.04)
Larsen et al., 2020 [1] Developmental trajectory of R2* in PU significantly interacted with overall cognitive score (p = 0.006) with poorer performance becoming increasingly associated with lower R2* levels; Developmental trajectories of R2* were most strongly associated with complex cognitive performance (p = 0.004) with significant association between R2* trajectory and social cognition (p = 0.031) and executive function (p = 0.032), No significant effect of R2* on memory performance (p = 0.39)
Li et al., 2015 [47] Decrease in manual dexterity score was significantly associated with increase in magnetic susceptibility in the GP and RN; In younger participants the susceptibility-dexterity correlation was significant for GP (p<0.01) but not RN (p = 0.028); In older participants the susceptibility-dexterity correlation was significant for RN (p<0.05) but not for GP (p = 0.11); Only GP magnetic susceptibility was a significant predictor of variance in manual dexterity score (with higher GP magnetic susceptibility associated with lower manual dexterity score)
Lu et al., 2015 [48] Compared to control group, cmTBI patients had significantly higher angle radian values in CN (p<0.001), LN (p<0.001), L-HP (p<0.05), R-HP (p<0.001), L-RN (p<0.05), R-RN (p<0.001), R-SN (p<0.001), splenium of CC (p<0.005); Cognitive score in the patient group were negatively correlated to angle radian values in the R-SN (r = -0.685, p<0.001)
Modica et al., 2015 [49] MS patients significantly more cognitively impaired then healthy controls; Mean phase significantly lower in patients with MS in TH, CN, PL; Mean phase of CN, PU, GP and PL but not TH correlated cognitive test scores when volume was controlled for (p<0.05)
Murakami et al., 2018 [50] 3 months after shunt surgery, brain-type Tf strongly correlated with MMSE scores (r = 0.697, p = 0.037) and FAB score (r = 0.727, p = 0.041); 12 months after shunt surgery, brain-type Tf moderately correlated MMSE scores (r = 0.549, p = 0.022) and FAB score (r = 0.373, p = 0.154); mRS scores were not associated with brain-type Tf before or after surgery
Penke et al., 2012 [51] Compared with the group without detectable Iron Deposits (IDs), those with IDs at age 72 had significantly lower general cognitive ability at age 70 (p = 0.043), and age 72 (p = 0.0004), but not at age 11 (p = 0.19); Censored correlations showed greater IQ at 11 was significantly associated with fewer iron deposits at age 72 (p = 0.0324, r = -0.19); Reading recognition tests showed significant negative association with iron deposits (r = -0.18, p = 0.0253); Iron deposits were significantly associated with lower general cognitive ability at age 70 (r = -0.27, p = 0.0015) and 72 (r = -0.31, p<0.0001)
Pinter et al., 2015 [52] Magnetisation transfer ration for normal appearing brain tissue explained 26.7% variance in overall cognition; Overall iron deposition did not account for variance in overall cognition significantly; Basal ganglia R2* explained 22.4% variance of cognitive efficiency; HP magnetic transfer ration of normal appearing brain tissue (22.4%) also accounted for memory variance; TH volume was the only predictor of memory function after multivariate modelling; The only predictor of cognitive efficiency after multivariate modelling was R2* in the basal ganglia (explaining 22.4% variance)
Qin et al., 2011 [53] R2* in HP, PC, PU and CN of AD significantly higher than control group (p<0.05); R2* in PC, HP and L-PU in mild AD group were significantly higher than in controls (p<0.05); R2* in HP, PC, PU and DN in patients with severe AD were significantly higher than the control and mild AD groups; MMMSE was negatively correlated with R2* and iron concentration in PC and HP in AD group (p<0.01)
Rodrigue et al., 2013 [54] Increased HP iron and smaller HP volume accounted for age-related memory deficits (p = 0.05) whereas, CN did not have this effect; Younger participants with larger HP and lower HP iron had the highest memory composite scores; Single indirect path modelling showed a negative indirect association of age with HC volume through increased HP iron concentration (p<0.0001) and advanced age was indirectly related to poorer memory performance through a shorter HP T2* and then smaller HP volume (p<0.0001)
Rodrigue et al., 2020 [55] Significant decline in performance across all levels of n-back tests (p<0.05) with increasing age but no iron interaction in this model (p>0.174); No association found between iron and performance in executive function performance
Salami et al., 2018 [56] Significant negative association between striatal R2* and coherence in connectivity of the CN (r = -0.41, p = 0.008) and PU (r = -0.32, p = 0.047); Significant association between striatal iron and coherence of connectivity in the CN resting-state network in the older group (r = -0.53, p = 0.04) but not in the younger group (r = -0.24, p = 0.27); Association between QSM and CN connectivity coherence confirmed significance (r = 0.398, p = 0.015) but the PU connectivity coherence was not significantly associated with QSM (p = 0.07); Significant positive association between coherence of PU networks and task performance with the dominant hand across age groups (p = 0.04); Significant association between striatal iron and motor performance with the dominant hand across the age groups (p = 0.047)
Schmalbrock et al., 2016 [57] Flanker test for inhibitory control was significantly associated with QSM in CN (p = 0.01) and anterior PU (p = 0.045); Stroop test for inhibitory control was not significantly associated with brain iron measures; Disease duration was significantly associated with QSM in the CN (p = 0.02); Sqrt (Flanker) was significantly associated with age adjusted QSM in the CN (p = 0.0058) and anterior PU (p = 0.016); Duration adjusted Expanded disability status score was significantly associated with age adjusted QSM in the posterior PU (p = 0.032) and age adjusted R2 in the CN (p = 0.014), PU (p = 0.0059, Anterior p = 0.0054, Posterior p = 0.019)
Smith et al., 2010 [58] Controls had significantly lower cortical redox iron than other groups (p<0.05); Controls had significantly less iron accumulation in the cerebellum but had high metal deposition in the purkinje cell layer; Iron accumulation did not occur not in purkinje cells for MCI brains but instead in spherical glial associated structures; MCI cases had significantly more iron accumulation than controls in the purkinje layer associated with glial cells
Steiger et al., 2016 [59] In ventral striatum there was a positive correlation between VLMT learning performance and Magnetic transfer (MT), but a negative correlation between VLMT recognition performance and R2*; VLMT learning performance was predicted by the ratio of MT/R2*
Sullivan et al., 2009 [60] Higher iron in CN predicted lower dementia rating scale score (r = -0.7, p = 0.0232; Rho = -0.56, p = 0.0944); Lower arithmetic score correlated higher iron in CN (r = −0.64, p = 0.0481; Rho = −0.70, p = 0.0359) and putamen (r = −0.78, p = 0.0077; Rho = −0.65, p = 0.0495); TH iron was predictive of Digit Symbol output (r = 0.77, p = 0.0088; Rho = 0.57, p = 0.0865), time taken to complete the test (r = −0.79, p = 0.0069; Rho = −0.56, p = 0.0909), and MMSE scores (r = 0.66, p = 0.0397; Rho = 0.47, p = 0.1611); In the two choice test CN iron correlated with longer reaction time by the left (r = 0.56, p = 0.0918) and right (r = 0.79, p = 0.0062) hands, higher GP iron correlated with longer reaction time by the right hand (r = 0.65, p = 0.0421) and higher PU iron correlated with longer movement time by the left (r = 0.70, p = 0.024) hand; Fine finger movement speed showed no significant relationship with iron estimates in any region; In the Digit Symbol grid, CN and TH iron accounted for 80% of the variance; Low TH iron (p = 0.0096) was a unique predictor of performance over the caudate iron measure (p = 0.5192)
Sun et al., 2017 [61] svMCI group had significantly lower composite, attention-executive, memory and language z scores than controls; significantly higher susceptibility in svMCI group over controls in R-HP (p<0.01), L-HP (p<0.01), R-PU (p<0.05); svMCI group had significantly negative correlation between sus in R-HP and memory z sore (p = 0.012); susceptibility in R-HP of svMCI group was positively correlated to language z score (p = 0.026); susceptibility in R-PU in the svMCI group was significantly negatively correlated to attention-executive z score (p = 0.033); composite z score not related to susceptibility
Thomas et al., 2020 [62] Increase in QSM in PD compared to controls in prefrontal cortex, R-PU and R-temporal cortex (p<0.05); Increased QSM in SN in PD compared to controls (p = 0.004); In PD patients there was susceptibility increase with decreasing MoCA scores in HP, TH, CN, caudal regions of ventromedial prefrontal cortex, regions of basal forebrain, R-PU and R-insular cortex; Increased absolute susceptibility with increased dementia risk score in PD patients (p<0.05); widespread QSM increases in patients with poor visual performance (p<0.05); PD group showed significant increase in susceptibility (p<0.05) with UPDRS- III in right PU
Valdes-Hernandez et al., 2015 [63] All 3 cognitive factors (Memory, Processing Speed and Fluid intelligence) were significantly negatively correlated with total Iron deposition (r = -0.165) at older age, even when controlling for all other health factors; No significant correlation between Iron deposition and cognition at 11 y/o
Van Bergen et al., 2016 [64] MCI and healthy controls differed significantly in MoCA, VMLT, BNT and WMS cognitive tests; Strong significant increase in susceptibility in APOe4 carriers of the MCI group in CN (p<0.001) and frontal, temporal, parietal and occipital cortices (p<0.001)
Wang et al., 2013 [65] Regions where MMSE score was significantly correlated to angle radian values were the R&L-cerebellar hemisphere, R&L-HP, R&L-RN, R-CN, R&L-LN, R&L-TH, and splenium of CC, where correlation coefficients were 0.36999, 0.3783, 0.40081, 0.40741, 0.2892, 0.2599, 0.2593, 0.40462, 0.26039, 0.54453, 0.46979, -0.28888 (P values = 0.00362, 0.00288, 0.00151, 0.00123, 0.02501, 0.04492, 0.04543, 0.00134, 0.0445, <0.001, <0.001, 0.02519, respectively)
Yang et al., 2018 [66] T2DM without MCI group had increased susceptibility in bilateral CN, HP, left PU and right SN compared to controls (p<0.05); T2DM with MCI group had significantly increased susceptibility in right CN, SN and left PU compared to T2DM without MCI group (p<0.05); Susceptibility values for right CN, SN and left PU were closely correlated to cognitive scores (r>-0.55, p<0.04)

CN = Caudate Nucleus, GP = Globus Pallidus, PU = Putamen, SN = Substantia Nigra, HP = Hippocampus, RN = Red Nucleus, DN = Dentate Nucleus, TH = thalamus, PA = Pallidum, AM = amygdala, WM = White Matter, PL = pulvinar nucleus of the thalamus, CC = corpus collosum.

Fig 2. Regional associations between iron and cognition.

Fig 2

Figure presents number of studies reporting significant association (p<0.05) between regional iron and cognition measures. *Pallidum had associations between regional iron and memory in one study [30] but had association in all cognitive measures except memory in a second study [42].

Discussion

Summary of evidence

This review analysed human studies in which brain iron and cognition were measured and their relationship assessed statistically. Many of studies assessed reported a significant relationship between total brain iron and general cognitive performance and many links between regional iron levels and specific measures of cognition were also reported. Memory function was the most frequently reported cognitive measure to be correlated with brain iron, however, this was the most frequently assessed cognitive outcome. Regions where iron was most frequently reported to correlate with memory performance were the Caudate nuclei, Hippocampus and Thalamus. All other regions were also associated with memory in at least one study except for the Globus Pallidus where regional iron had no reported associations with memory. The associations between the caudate, hippocampus and thalamus iron and memory are somewhat unsurprising as each of these regions are known to be involved in different facets of memory function [6769] and so it is plausible that disruption of these circuits via iron accumulation would confer memory dysfunction. The efficacy of interactions between the caudate and hippocampus in memory function has been associated with availability of dopamine receptors [70, 71], which has in turn been proposed as having a potential role in iron accumulation [72]. Studies have suggested that iron and dopamine can interact to induce oxidative stress and neurodegeneration by forming a toxic couple [72]. Animal studies have also demonstrated that iron deficient mice and rats show decreased dopamine transporter and receptor levels and general dopaminergic dysfunction [73, 74]. This suggests that with an increase iron, there could be an increase in dopamine receptors and transporters, enhancing toxic coupling between iron and dopamine and thus increasing neurodegeneration in dopamine rich regions, however, this requires further investigation.

Furthermore, higher iron levels in the caudate nuclei were also consistently reported to correlate to poorer general cognitive performance. However, the putamen had the most reported associations with general cognition, with the Globus Pallidus and the Substantia Nigra also being associated with general cognition in more than one study. The putamen has roles in many different neurological functions such as, sensory and motor information processing, learning and language [7577]. This could explain the consistency of reports that iron accumulation here is associated with poorer general cognitive performance, further suggesting that iron accumulation causes atrophy which leads to a localised disruption of function.

Although assessed in less of the studies reviewed, there were associations between reduced motor function and increased striatal iron content, as well as, increased iron in the Putamen and increased disability scores, such as, Dementia rating scale, Extended disability status score and the UPDRS-III for rating of Parkinson’s pathology. Due to its many neurological roles and connections, atrophy in the Putamen is known to be involved in pathology of several diseases such as, Parkinson’s disease, Multiple Sclerosis and Dementia with Lewy Bodies [7881]. The striatum consists of the caudate and putamen and is crucial for connections to the basal ganglia which is heavily involved in motor control [82]. These associations therefore suggest that iron accumulation is capable of either causing atrophy or is accompanied by atrophy, which in turn causes regional damage that can interfere with circuitry in the brain. This is in line with the findings of several of the included studies that increases in regional brain iron were strongly associated with regional volume decrease [34, 35, 49, 54], suggesting that brain iron increase is correlated with atrophy.

Whilst not evaluated in the included studies, differences in iron status have been observed between sexes particularly during development. Larsen et al. observed these differences in their 2020 study, which determined that male brain iron levels plateau at an earlier age than in females in some brain regions. Due to this later plateau during development females generally begin adulthood with higher brain iron levels than men. However, at older age, females are shown to have generally lower iron stores in some brain regions than males, potentially due to menstruation [8385]. Female brain iron deficit mediated by menstruation would however, be highly variable, dependent on the characteristics of an individuals’ menstruation (i.e. menstruation pattern, heaviness of blood loss etc.) [83]. This may put females at a lower risk of brain iron-mediated cognitive impairment, however the effects of sex-mediated brain iron on cognition have not been extensively studied.

All studies included in this review controlled for sex during their analyses. Fifteen of the included studies assessed sex-mediated brain iron differences statistically; 1 study found that while temporal iron levels did not significantly differ between men and women, cerebellar iron was significantly higher in males compared to females [27]; 1 studies found significantly higher hippocampal iron in men compared to women [28]; 1 study found that regional brain iron in women plateaus later than in men during development [1] and the remaining 12 studies observed no significant difference in brain iron in any assessed region between males and females [29, 31, 3436, 38, 42, 44, 47, 51, 54, 63].

Although primarily focusing on the associations between brain iron and cognition, some of the papers reviewed did provide insight into potential mechanisms for this relationship. It has been previously reported that iron in the brain tends to localise to protein aggregates and some studies have shown that iron plays a role in the toxicity of some of these aggregates [8689]. In fact, when amyloid β (Aβ) is complexed with iron it can induce ROS via Fenton’s reaction leading to oxidative stress and activation of the Bcl-2 apoptotic pathway [18, 19]. Iron has also been shown to localise with protein aggregates such as tau and amyloid beta in animal models for AD and PD [88, 90, 91]. Several of the studies included in this review reported that iron was localised to Aβ plaques and neurofibrillary tangles [27, 58]. A study by Ayton et al. [27], included in this review, found that brain iron level mediated 17% of the effect of Neurofibrillary tangles on cognitive performance. This, taken with the afore mentioned literature, suggests that iron could amplify neurodegenerative processes such as protein misfolding, rather than being a primary cause or effect of disease.

Limitations

Whilst this article was able to provide a comprehensive review of the literature investigating the relationship between brain iron and cognition, there were several limitations to this study. Firstly, there was a wide variety of methods for measuring both brain iron and cognition and this must be considered when comparing the included studies. Secondly, although a thorough search of the literature was conducted, it is possible that relevant studies were missed and thus not included. Furthermore, all included studies were published articles or theses and thus there is an element of publication bias in this review that must be considered. Additionally, some of the studies included in this review had relatively small sample sizes which may reduce the power of some of the conclusions made. The participants all bar one of the studies in this review were adults and so the findings cannot be applied to children or adolescents. Finally, the potential mechanisms by which iron accumulation in the brain could cause cognitive dysfunction were not assessed in this review and remain unclear.

Conclusions

To conclude, this review has investigated the effects of brain iron on aspects of cognition. There is consistent evidence in the studies reviewed that in adulthood, an increase in brain iron had a detrimental effect on cognitive ability. However, it seems that iron accumulates heterogeneously across brain regions and when only some regions have high iron, their specific function can be impaired. In this way, increased iron in the Caudate nuclei, Hippocampus and Thalamus is consistently reported to correlate to poorer memory performance; whereas, increased iron in the putamen was more consistently reported to correlate to poorer general cognition. These findings strongly suggest an effect of brain iron on cognition and this relationship should therefore be investigated further. Going forward, it is important to determine whether iron is a primary cause of brain atrophy or whether brain iron accumulation is a secondary effect of brain atrophy. Regardless of the mechanisms underlying the relationship between brain iron and cognition, MRI techniques for quantifying brain iron therefore show promise as a potential non-invasive biomarker for age-related cognitive decline.

Supporting information

S1 Checklist. PRISMA 2009 checklist.

(DOCX)

Acknowledgments

The authors would like to thank the Roland Sutton Academic Trust for their financial support.

Data Availability

All relevant data are within the manuscript and its supporting information files.

Funding Statement

Principal Grant Holder: GW Funder: The Roland Sutton Academic Trust https://www.abdn.ac.uk/ims/research/abic/roland-sutton-academic-trust-1427.php Sponsers only provided financial support.

References

  • 1.Larsen B, Bourque J, Moore TM, Adebimpe A, Calkins ME, Elliott MA, et al. Longitudinal development of brain iron is linked to cognition in youth. The Journal of Neuroscience. 2020. January 27;40(9):1810–8. 10.1523/JNEUROSCI.2434-19.2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. NMR in Biomedicine. 2017;30(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.White AR, Kanninen KM, Crouch PJ. Editorial: Metals and neurodegeneration: Restoring the balance Vol. 7, Frontiers in Aging Neuroscience. Frontiers Research Foundation; 2015. p. 127 10.3389/fnagi.2015.00127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hare D, Ayton S, Bush A, Lei P. A delicate balance: Iron metabolism and diseases of the brain. Vol. 5, Frontiers in Aging Neuroscience. 2013. p. 1–19. 10.3389/fnagi.2013.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hadzhieva M, Kirches E, Mawrin C. Review: Iron metabolism and the role of iron in neurodegenerative disorders Vol. 40, Neuropathology and Applied Neurobiology. Blackwell Publishing Ltd; 2014. p. 240–57. 10.1111/nan.12096 [DOI] [PubMed] [Google Scholar]
  • 6.Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders Vol. 13, The Lancet Neurology. Lancet Publishing Group; 2014. p. 1045–60. 10.1016/S1474-4422(14)70117-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Deistung A, Schweser F, Reichenbach JR. Overview of quantitative susceptibility mapping. NMR in Biomedicine. 2017;30:e3569. [DOI] [PubMed] [Google Scholar]
  • 8.Haacke EM, Liu S, Buch S, Zheng W, Wu D, Ye Y. Quantitative susceptibility mapping: Current status and future directions Vol. 33, Magnetic Resonance Imaging. Elsevier Inc.; 2015. p. 1–25. 10.1016/j.mri.2014.09.004 [DOI] [PubMed] [Google Scholar]
  • 9.Li W, Wu B, Batrachenko A, Bancroft-Wu V, Morey RA, Shashi V, et al. Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Human Brain Mapping. 2014;35(6):2698–713. 10.1002/hbm.22360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu C, Li W, Tong KA, Yeom KW, Kuzminski S. Susceptibility-Weighted Imaging and Quantitative Susceptibility Mapping in the Brain HHS Public Access. J Magn Reson Imaging. 2015;42(1):23–41. 10.1002/jmri.24768 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicology Letters. 1995;82–83(C):969–74. [DOI] [PubMed] [Google Scholar]
  • 12.Abadin H, Bartzokis G, Bayer T, Brown D, Bush A, Chang C, et al. Metal Ions in Life Sciences: Neurodegenerative Diseases and Metal Ions. 1st ed Sigel A, Sigel H, Sigel R, editors. Chichester: John Wiley and Sons Ltd; 2006. [Google Scholar]
  • 13.Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D. Heme oxygenase-1 and neurodegeneration: Expanding frontiers of engagement. Journal of Neurochemistry. 2009;110(2):469–85. 10.1111/j.1471-4159.2009.06160.x [DOI] [PubMed] [Google Scholar]
  • 14.Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cellular and Molecular Life Sciences. 2016;73(17):3221–47. 10.1007/s00018-016-2223-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free Radicals: Key to Brain Aging and Heme Oxygenase as a Cellular Response to Oxidative Stress. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2004;59(5):M478–93. [DOI] [PubMed] [Google Scholar]
  • 16.Wang ZB, Liu JY, Xu XJ, Mao XY, Zhang W, Zhou HH, et al. Neurodegeneration with brain iron accumulation: Insights into the mitochondria dysregulation. Biomedicine and Pharmacotherapy [Internet]. 2019;118:109068 Available from: 10.1016/j.biopha.2019.109068 [DOI] [PubMed] [Google Scholar]
  • 17.Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson’s disease. Journal of Cerebral Blood Flow and Metabolism. 2015;35:747–50. 10.1038/jcbfm.2015.32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Rival T, Page RM, Chandraratna DS, Sendall TJ, Ryder E, Liu B, et al. Fenton chemistry and oxidative stress mediate the toxicity of the -amyloid peptide in a Drosophila model of Alzheimer’s disease. European Journal of Neuroscience. 2009. April;29(7):1335–47. 10.1111/j.1460-9568.2009.06701.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kuperstein F, Yavin E. Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity. Journal of Neurochemistry. 2003. July;86(1):114–25. 10.1046/j.1471-4159.2003.01831.x [DOI] [PubMed] [Google Scholar]
  • 20.Wengenack TM, Reyes DA, Curran GL, Borowski BJ, Lin J, Preboske GM, et al. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. NeuroImage. 2011. January 1;54(1):113–22. 10.1016/j.neuroimage.2010.08.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang Y, Liu T. Quantitative Susceptibility Mapping (QSM): Decoding MRI Data for a Tissue Magnetic Biomarker. Magnetic Resonance in Medicine. 2015;73:82–102. 10.1002/mrm.25358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Barbosa JHO, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, et al. Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2*. Magnetic Resonance Imaging. 2015. June 1;33(5):559–65. 10.1016/j.mri.2015.02.021 [DOI] [PubMed] [Google Scholar]
  • 23.Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. Journal of Neurochemistry. 1958;3(1):41–51. 10.1111/j.1471-4159.1958.tb12607.x [DOI] [PubMed] [Google Scholar]
  • 24.Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage. 2012. September;62(3):1593–9. 10.1016/j.neuroimage.2012.05.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ (Online) [Internet]. 2009;339:332–6. Available from: 10.1136/bmj.b2535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Molecular Psychiatry [Internet]. 2019;1–18. Available from: 10.1038/s41380-019-0375-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bartzokis G, Lu PH, Tingus K, Peters DG, Amar CP, Tishler TA, et al. Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology. 2011. June;36(7):1375–84. 10.1038/npp.2011.22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Blasco G, Puig J, Daunis-i-Estadella J, Molina X, Xifra G, Fernández-Aranda F, et al. Brain iron overload, insulin resistance, and cognitive performance in obese subjects: A preliminary MRI case-control study. Diabetes Care. 2014;37(11):3076–83. 10.2337/dc14-0664 [DOI] [PubMed] [Google Scholar]
  • 30.Blasco G, Moreno-Navarrete JM, Rivero M, Pérez-Brocal V, Garre-Olmo J, Puig J, et al. The gut metagenome changes in parallel to waist circumference, brain iron deposition, and cognitive function. Journal of Clinical Endocrinology and Metabolism. 2017;102(8):2962–73. 10.1210/jc.2017-00133 [DOI] [PubMed] [Google Scholar]
  • 31.Carpenter KLH, Li W, Wei H, Wu B, Xiao X, Liu C, et al. Magnetic susceptibility of brain iron is associated with childhood spatial IQ. NeuroImage [Internet]. 2016;132:167–74. Available from: 10.1016/j.neuroimage.2016.02.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Chen BT, Ghassaban K, Jin T, Patel SK, Ye N, Sun C-L, et al. Subcortical brain iron deposition and cognitive performance in older women with or without breast cancer receiving adjuvant chemotherapy: a pilot MRI study. Magnetic Resonance Imaging. 2018;54:218–24. 10.1016/j.mri.2018.07.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Darki F, Nemmi F, Möller A, Sitnikov R, Klingberg T. Quantitative susceptibility mapping of striatum in children and adults, and its association with working memory performance. NeuroImage [Internet]. 2016;136:208–14. Available from: 10.1016/j.neuroimage.2016.04.065 [DOI] [PubMed] [Google Scholar]
  • 34.Daugherty AM. Accumulation of subcortical iron as a modifier of volumetric and cognitive decline in healthy aging: Two longitudinal studies [Internet]. Wayne State University Dissertations. 2014. Available from: https://manchester.idm.oclc.org/login?url = https://search.proquest.com/docview/1615100570?accountid=12253%0A http://man-fe.hosted.exlibrisgroup.com/openurl/44MAN/44MAN_services_page?genre=dissertations+%26+theses&atitle=&author=Daugherty%2C+Ana+M.&volume=&i
  • 35.Daugherty AM, Haacke EM, Raz N. Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults. Journal of Neuroscience. 2015;35(17):6731–43. 10.1523/JNEUROSCI.4717-14.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Daugherty AM, Hoagey DA, Kennedy KM, Rodrigue KM. Genetic Predisposition for Inflammation Exacerbates Effects of Striatal Iron Content on Cognitive Switching Ability in Healthy Aging. NeuroImage [Internet]. 2019;185:471–8. Available from: file:///C:/Users/Carla Carolina/Desktop/Artigos para acrescentar na qualificação/The impact of birth weight on cardiovascular disease risk in the.pdf 10.1016/j.neuroimage.2018.10.064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T, et al. Correlation of iron in the hippocampus with MMSE in patients with alzheimer’s disease. Journal of Magnetic Resonance Imaging. 2009;29:793–8. 10.1002/jmri.21730 [DOI] [PubMed] [Google Scholar]
  • 38.Du L, Zhao Z, Cui A, Zhu Y, Zhang L, Liu J, et al. Increased Iron Deposition on Brain Quantitative Susceptibility Mapping Correlates with Decreased Cognitive Function in Alzheimer’s Disease. ACS Chemical Neuroscience. 2018;9(7):1849–57. 10.1021/acschemneuro.8b00194 [DOI] [PubMed] [Google Scholar]
  • 39.Fujiwara E, Kmech JA, Cobzas D, Sun H, Seres P, Blevins G, et al. Cognitive implications of deep gray matter iron in multiple sclerosis. American Journal of Neuroradiology. 2017;38:942–8. 10.3174/ajnr.A5109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gao L, Jiang Z, Cai Z, Cai M, Zhang Q, Ma Y, et al. Brain iron deposition analysis using susceptibility weighted imaging and its association with body iron level in patients with mild cognitive impairment. Molecular Medicine Reports. 2017;16(6):8209–15. 10.3892/mmr.2017.7668 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ge Y, Jensen JH, Lu H, Helpern JA, Miles L, Inglese M, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. American Journal of Neuroradiology. 2007;28:1639–44. 10.3174/ajnr.A0646 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ghadery C, Pirpamer L, Hofer E, Langkammer C, Petrovic K, Loitfelder M, et al. R2* mapping for brain iron: Associations with cognition in normal aging. Neurobiology of Aging [Internet]. 2015;36(2015):925–32. Available from: 10.1016/j.neurobiolaging.2014.09.013 [DOI] [PubMed] [Google Scholar]
  • 43.Haller S, Bartsch A, Nguyen D, Rodriguez C, Emch J, Gold G, et al. Cerebral Microhemorrhage and Iron Deposition in Mild Cognitive Impairment. Radiology. 2010;257(3):764–73. 10.1148/radiol.10100612 [DOI] [PubMed] [Google Scholar]
  • 44.Hect JL, Daugherty AM, Hermez KM, Thomason ME. Developmental variation in regional brain iron and its relation to cognitive functions in childhood. Developmental Cognitive Neuroscience [Internet]. 2018;34:18–26. Available from: 10.1016/j.dcn.2018.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.House MJ, st. Pierre TG, Foster JK, Martins RN, Clarnette R. Quantitative MR imaging R 2 relaxometry in elderly participants reporting memory loss. American Journal of Neuroradiology. 2006;27:430–9. [PMC free article] [PubMed] [Google Scholar]
  • 46.Kalpouzos G, Garzón B, Sitnikov R, Heiland C, Salami A, Persson J, et al. Higher Striatal Iron Concentration is Linked to Frontostriatal Underactivation and Poorer Memory in Normal Aging. Cerebral Cortex. 2017;27(6):3427–36. 10.1093/cercor/bhx045 [DOI] [PubMed] [Google Scholar]
  • 47.Li W, Langkammer C, Chou Y-H, Petrovic K, Schmidt R, Song AW, et al. Association between Increased Magnetic Susceptibility of Deep Gray Matter Nuclei and Decreased Motor Function in Healthy Adults. NeuroImage. 2015;105(1):45–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Lu L, Cao H, Wei X, Li Y, Li W. Iron Deposition Is Positively Related to Cognitive Impairment in Patients with Chronic Mild Traumatic Brain Injury: Assessment with Susceptibility Weighted Imaging. BioMed Research International. 2015;2015(470676):1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Modica CM, Zivadinov R, Dwyer MG, Bergsland N, Weeks AR, Benedict RHB. Iron and volume in the deep gray matter: Association with cognitive impairment in multiple sclerosis. American Journal of Neuroradiology. 2015;36:57–62. 10.3174/ajnr.A3998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Murakami Y, Matsumoto Y, Hoshi K, Ito H, Fuwa TJ, Yamaguchi Y, et al. Rapid increase of “brain-type” transferrin in cerebrospinal fluid after shunt surgery for idiopathic normal pressure hydrocephalus: A prognosis marker for cognitive recovery. Journal of Biochemistry. 2018;164(3):205–13. 10.1093/jb/mvy043 [DOI] [PubMed] [Google Scholar]
  • 51.Penke L, Valdés Hernandéz MC, Maniega SM, Gow AJ, Murray C, Starr JM, et al. Brain iron deposits are associated with general cognitive ability and cognitive aging. Neurobiology of Aging [Internet]. 2012;33(2012):510–7. Available from: 10.1016/j.neurobiolaging.2010.04.032 [DOI] [PubMed] [Google Scholar]
  • 52.Pinter D, Khalil M, Pichler A, Langkammer C, Ropele S, Marschik PB, et al. Predictive value of different conventional and non-conventional MRI-parameters for specific domains of cognitive function in multiple sclerosis. NeuroImage: Clinical [Internet]. 2015;7:715–20. Available from: 10.1016/j.nicl.2015.02.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Qin Y, Zhu W, Zhan C, Zhao L, Wang J, Tian Q, et al. Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2’ mapping. Journal of Huazhong University of Science and Technology—Medical Science. 2011;31(4):578–85. [DOI] [PubMed] [Google Scholar]
  • 54.Rodrigue KM, Daugherty AM, Haacke EM, Raz N. The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cerebral Cortex. 2013;23:1533–41. 10.1093/cercor/bhs139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Rodrigue KM, Daugherty AM, Foster CM, Kennedy KM. Striatal iron content is linked to reduced fronto-striatal brain function under working memory load. NeuroImage [Internet]. 2020;210(2020):116544 Available from: 10.1016/j.neuroimage.2020.116544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Salami A, Avelar-Pereira B, Garzón B, Sitnikov R, Kalpouzos G. Functional coherence of striatal resting-state networks is modulated by striatal iron content. NeuroImage. 2018;183:495–503. 10.1016/j.neuroimage.2018.08.036 [DOI] [PubMed] [Google Scholar]
  • 57.Schmalbrock P, Prakash RS, Schirda B, Janssen A, Yang GK, Russell M, et al. Basal ganglia iron in patients with multiple sclerosis measured with 7T quantitative susceptibility mapping correlates with inhibitory control. American Journal of Neuroradiology. 2016;37:439–46. 10.3174/ajnr.A4599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Cohen ML, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimer’s Disease. 2010;19(1):363–72. 10.3233/JAD-2010-1239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Steiger TK, Weiskopf N, Bunzeck N. Iron level and myelin content in the ventral striatum predict memory performance in the aging brain. Journal of Neuroscience. 2016;36(12):3552–8. 10.1523/JNEUROSCI.3617-15.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Sullivan EV, Adalsteinsson E, Rohlfing T, Pfefferbaum A. Relevance of Iron Deposition in Deep Gray Matter Brain Structures to Cognitive and Motor Performance in Healthy Elderly Men and Women: Exploratory Findings. Brain Imaging and Behavior. 2009;3(2):167–75. 10.1007/s11682-008-9059-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Sun Y, Ge X, Han X, Cao W, Wang Y, Ding W, et al. Characterizing brain iron deposition in patients with subcortical vascular mild cognitive impairment using quantitative susceptibility mapping: A potential biomarker. Frontiers in Aging Neuroscience. 2017;9(81):1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2020;91:418–25. 10.1136/jnnp-2019-322042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Valdés Hernández M, Ritchie S, Glatz A, Allerhand M, Muñoz Maniega S, Gow AJ, et al. Brain iron deposits and lifespan cognitive ability. Age. 2015;37(100):1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.van Bergen JMG, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC, et al. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Scientific Reports. 2016;6(35514):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Wang D, Zhu D, Wei X-E, Li Y-H, Li W-B. Using susceptibility-weighted images to quantify iron deposition differences in amnestic mild cognitive impairment and Alzheimer’s disease. Neurol India [Internet]. 2013;61:26–34. Available from: http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2013;volume=61;issue=1;spage=26;epage=34;aulast=Wang 10.4103/0028-3886.107924 [DOI] [PubMed] [Google Scholar]
  • 66.Yang Q, Zhou L, Liu C, Liu D, Zhang Y, Li C, et al. Brain iron deposition in type 2 diabetes mellitus with and without mild cognitive impairment—an in vivo susceptibility mapping study. Brain Imaging and Behavior [Internet]. 2018;12:1479–87. Available from: 10.1007/s11682-017-9815-7 [DOI] [PubMed] [Google Scholar]
  • 67.Newsome MR, Durgerian S, Mourany L, Scheibel RS, Lowe MJ, Beall EB, et al. Disruption of caudate working memory activation in chronic blast-related traumatic brain injury. NeuroImage: Clinical [Internet]. 2015;8:543–53. Available from: 10.1016/j.nicl.2015.04.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Bick SK, Patel SR, Katnani HA, Peled N, Widge A, Cash SS, et al. Caudate stimulation enhances learning. Brain. 2019;142:2930–7. 10.1093/brain/awz254 [DOI] [PubMed] [Google Scholar]
  • 69.Roozendaal B, Mcgaugh JL. Memory modulation. Behavioral Neuroscience. 2011;125(6):797–824. 10.1037/a0026187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Nyberg L, Karalija N, Salami A, Andersson M, Wåhlin A, Kaboovand N, et al. Dopamine D2 receptor availability is linked to hippocampal-caudate functional connectivity and episodic memory. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(28):7918–23. 10.1073/pnas.1606309113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Nour MM, Dahoun T, McCutcheon RA, Adams RA, Wall MB, Howes OD. Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory. eLife. 2019;8:e45045 10.7554/eLife.45045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Hare DJ, Double KL. Iron and dopamine: A toxic couple. Brain. 2016;139:1026–35. 10.1093/brain/aww022 [DOI] [PubMed] [Google Scholar]
  • 73.Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacology Biochemistry and Behavior. 2001;69(3–4):409–18. [DOI] [PubMed] [Google Scholar]
  • 74.Erikson KM, Jones BC, Beard JL. Iron Deficiency Alters Dopamine Transporter Functioning in Rat Striatum. The Journal of Nutrition. 2000;130(11):2831–7. 10.1093/jn/130.11.2831 [DOI] [PubMed] [Google Scholar]
  • 75.Jackson SAW, Horst NK, Axelsson SFA, Horiguchi N, Cockcroft GJ, Robbins TW, et al. Selective Role of the Putamen in Serial Reversal Learning in the Marmoset. Cerebral Cortex. 2019;29(1):447–60. 10.1093/cercor/bhy276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Vicente AF, Bermudez MA, Romero MDC, Perez R, Gonzalez F. Putamen neurons process both sensory and motor information during a complex task. Brain Research [Internet]. 2012;1466:70–81. Available from: 10.1016/j.brainres.2012.05.037 [DOI] [PubMed] [Google Scholar]
  • 77.Viñas-Guasch N, Wu YJ. The role of the putamen in language: a meta-analytic connectivity modeling study. Brain Structure and Function. 2017;222(9):3991–4004. 10.1007/s00429-017-1450-y [DOI] [PubMed] [Google Scholar]
  • 78.Hünerli D, Emek-Savaş DD, Çavuşoğlu B, Dönmez Çolakoğlu B, Ada E, Yener GG. Mild cognitive impairment in Parkinson’s disease is associated with decreased P300 amplitude and reduced putamen volume. Clinical Neurophysiology. 2019;130(8):1208–17. 10.1016/j.clinph.2019.04.314 [DOI] [PubMed] [Google Scholar]
  • 79.Cousins DA, Burton EJ, Burn D, Gholkar AR, Mckeith I, O’Brien JT. Atrophy of the putamen in dementia with lewy bodies but not Alzheimer’s disease: An MRI study. Neurology. 2003;61(9):1191–5. 10.1212/01.wnl.0000091889.20347.30 [DOI] [PubMed] [Google Scholar]
  • 80.Manes JL, Tjaden K, Parrish T, Simuni T, Roberts A, Greenlee JD, et al. Altered resting-state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson’s disease. Brain and Behavior. 2018;8(9):1–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Krämer J, Meuth SG, Tenberge JG, Schiffler P, Wiendl H, Deppe M. Early and degressive putamen atrophy in multiple sclerosis. International Journal of Molecular Sciences. 2015;16(10):23195–209. 10.3390/ijms161023195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Öztekin L, Nicole M, Badre D. Striatal plasticity and basal ganglia circuit function. Neuron [Internet]. 2008;60(4):543–54. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf 10.1016/j.neuron.2008.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Whitfield J. B., Treloar S., Zhu G., Powell L. W. & Martin N. G. Relative importance of female-specific and non-female-specific effects on variation in iron stores between women. Br. J. Haematol. 2003; 120:860–866. 10.1046/j.1365-2141.2003.04224.x [DOI] [PubMed] [Google Scholar]
  • 84.House M. J., St. Pierre T. G., Milward E. A., Bruce D. G. & Olynyk J. K. Relationship between brain R2 and liver and serum iron concentrations in elderly men. Magn. Reson. Med. 2010; 63:275–281. 10.1002/mrm.22263 [DOI] [PubMed] [Google Scholar]
  • 85.Bartzokis G. et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007; 28:414–423 10.1016/j.neurobiolaging.2006.02.005 [DOI] [PubMed] [Google Scholar]
  • 86.Gong NJ, Dibb R, Bulk M, van der Weerd L, Liu C. Imaging beta amyloid aggregation and iron accumulation in Alzheimer’s disease using quantitative susceptibility mapping MRI. NeuroImage [Internet]. 2019;191:176–85. Available from: 10.1016/j.neuroimage.2019.02.019 [DOI] [PubMed] [Google Scholar]
  • 87.Yamamoto A, Shin R, Hasegawa K, Naiki H, Sato H, Yoshimasu F, et al. Iron (III) induces aggregation of hyperphosphorylated s and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer ‘ s disease. Journal of Neurochemistry. 2002;82:1137–47. 10.1046/j.1471-4159.2002.t01-1-01061.x [DOI] [PubMed] [Google Scholar]
  • 88.Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, et al. Iron promotes the toxicity of amyloid β peptide by impeding its ordered aggregation. Journal of Biological Chemistry. 2011;286(6):4248–56. 10.1074/jbc.M110.158980 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Joppe K, Roser AE, Maass F, Lingor P. The contribution of iron to protein aggregation disorders in the central nervous system. Frontiers in Neuroscience. 2019;13(January):1–11. 10.3389/fnins.2019.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Telling ND, Everett J, Collingwood JF, Dobson J, van der Laan G, Gallagher JJ, et al. Iron Biochemistry is Correlated with Amyloid Plaque Morphology in an Established Mouse Model of Alzheimer’s Disease. Cell Chemical Biology [Internet]. 2017;24:1205–1215.e3. Available from: 10.1016/j.chembiol.2017.07.014 [DOI] [PubMed] [Google Scholar]
  • 91.Rao SS, Adlard PA. Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration. Frontiers in Molecular Neuroscience. 2018;11(August):1–13. 10.3389/fnmol.2018.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Efthimios M C Skoulakis

24 Aug 2020

PONE-D-20-20440

The impact of brain iron accumulation on cognition: A systematic review

PLOS ONE

Dear Dr. Spence,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Although your manuscript was well-received some minor clarifications and corrections are in order. Please thoroughly address all points below.

Please submit your revised manuscript by Oct 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Efthimios M. C. Skoulakis, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: #Referee

Comments to the Corresponding Author

PONE-D-20-20440

The authors have invested in a systematic approach to compare and evaluate the current literature and explore the relationship between brain iron and cognition. Identifying that iron appears to accumulate heterogeneously in regions of the brain and when only a few regions have a high iron content, its specific function may be deficient. Thus, increase iron in the caudate nuclei, hippocampus and thalamus is correlated with lower memory performance; whereas, increase iron in the putamen has been reported more consistently to correlate with poorer general cognition. The data presented here is very interesting, and the study design was generally successful.

However, the following weaknesses and improvements must be considered:

Point 1. However, according to Bartzokis et al. (2007) ferritin iron levels are higher in men than in women, which may contribute to the risk of developing neurodegenerative diseases at an early age. In this review, the gender factor was not discussed, according to the studies consulted, there would be changes in iron levels in women? And what would be the average age of both sexes attributed to cognitive impairment due to high levels of iron?

Point 2. It is suggested that there is more work /reflection on how high levels of iron act on the nervous system and cause cognitive alterations.

Line-By-Line

Point 3. Line 41- “In the healthy adult brain”. Please specify whether the quote refers to humans?

Point 4. Line 54- define ROS before using the acronym.

Point 5. Line 56- What damage excessive ROS generation can cause at the brain level, how neurodegeneration can occur via Fenton Reaction?

Point 6. Line 84- PD e AD previously abbreviated.

Point 7. Line 89- The systematic review brings gaps to be answered and hypotheses to be raised, the addition of a hypothesis to the study is encouraged.

Point 8. Line 115- define HS before using the acronym.

Point 9. Line 142- In this sentence it indicates that 43 studies were used, however, in Table 2 and Table 3 there is a citation of 41 studies.

Point 10. Line 143- Figure 1 is somewhat unreadable.

Point 11. Line 149 and 157- Standardize the use of abbreviations in tables.

Point 12. Line 126-127- Previously abbreviated.

Point 13. Line 237- define Aβ before using the acronym.

Point 14. Line 253-“all included studies were published articles or theses”. It is necessary to insert in the material and methods the use of theses in this review.

Point 15. Line 265-267- The insertion of a graphic scheme is strongly encouraged, making these possible correlations.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Notes PONE-D-20-20440.docx

PLoS One. 2020 Oct 15;15(10):e0240697. doi: 10.1371/journal.pone.0240697.r002

Author response to Decision Letter 0


9 Sep 2020

Dear Sir/Madam,

Manuscript title: The impact of brain iron accumulation on cognition: A systematic review

We thank the reviewers for their time and comments on the above titled manuscript. We have edited the manuscript to address these comments and include a revised submission with these revisions highlighted for your use. Below we have detailed how we have addressed each point made in the referee’s decision letter and hope that the revised manuscript now meets PLOS ONE’s publication criteria.

“Point 1. However, according to Bartzokis et al. (2007) ferritin iron levels are higher in men than in women, which may contribute to the risk of developing neurodegenerative diseases at an early age. In this review, the gender factor was not discussed, according to the studies consulted, there would be changes in iron levels in women? And what would be the average age of both sexes attributed to cognitive impairment due to high levels of iron?” An additional paragraph has been added into the discussion to address the current evidence surrounding sex-mediated brain iron differences. Statistical assessments of gender effect on brain iron in the studies included for review are also detailed in this paragraph. See lines 239-255

“Point 2. It is suggested that there is more work /reflection on how high levels of iron act on the nervous system and cause cognitive alterations.” More has been specified regarding the mechanisms by which iron can induce and amplify oxidative damage and eventually lead to neurodegeneration. See introduction section.

“Point 3. Line 41- “In the healthy adult brain”. Please specify whether the quote refers to humans?” This specification has now been made in line 41.

“Point 4. Line 54- define ROS before using the acronym.” This abbreviation has now been defined upon first mention in line 54.

“Point 5. Line 56- What damage excessive ROS generation can cause at the brain level, how neurodegeneration can occur via Fenton Reaction?” We have added extra information to this paragraph to further outline the role of ROS and Fenton’s reaction in neurodegeneration. See lines 54-61.

“Point 6. Line 84- PD e AD previously abbreviated.” These have now been abbreviated. See line 88.

“Point 7. Line 89- The systematic review brings gaps to be answered and hypotheses to be raised, the addition of a hypothesis to the study is encouraged.” A key hypothesis has now been defined in lines 92-93 of the concluding introductory paragraph.

“Point 8. Line 115- define HS before using the acronym.” This has now been defined as the authors full name, rather than using initials. See line 120.

“Point 9. Line 142- In this sentence it indicates that 43 studies were used, however, in Table 2 and Table 3 there is a citation of 41 studies.” and “Point 10. Line 143- Figure 1 is somewhat unreadable.”

This point has highlighted an error in this sentence and in the flow chart of figure 1. The sentence mentioned has now been changed and a new version of figure 1, also altered to improve readability has been submitted with this resubmission.

“Point 11. Line 149 and 157- Standardize the use of abbreviations in tables.” Abbreviations in all tables have now been standardised.

“Point 12. Line 126-127- Previously abbreviated.” We were unable to determine what this point was referring to, but have checked abbreviations between line 157 and 237.

“Point 13. Line 237- define Aβ before using the acronym.” This has now been rectified in line 262.

“Point 14. Line 253-“all included studies were published articles or theses”. It is necessary to insert in the material and methods the use of theses in this review.” This has now been specified in lines 121-122 of the Methods section of this submission.

“Point 15. Line 265-267- The insertion of a graphic scheme is strongly encouraged, making these possible correlations.” Figure 2 shows these correlations in a graphic scheme and has been resubmitted with the paper in a higher quality format.

Yours Faithfully,

Holly Spence

Post Graduate Researcher

Direct Phone: 07519122260

Email: h.spence.19@abdn.ac.uk

Decision Letter 1

Efthimios M C Skoulakis

1 Oct 2020

The impact of brain iron accumulation on cognition: A systematic review

PONE-D-20-20440R1

Dear Holly Spence,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Efthimios M. C. Skoulakis, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Efthimios M C Skoulakis

2 Oct 2020

PONE-D-20-20440R1

The impact of brain iron accumulation on cognition: A systematic review

Dear Dr. Spence:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Efthimios M. C. Skoulakis

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2009 checklist.

    (DOCX)

    Attachment

    Submitted filename: Notes PONE-D-20-20440.docx

    Data Availability Statement

    All relevant data are within the manuscript and its supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES